Brain Metastases Program

In December, 2012, the USFDA granted Diffusion Pharmaceuticals an Orphan Designation for the use of TSC in brain metastases. Planning for a clinical trial testing TSC in this indication is on-going, with enrollment expected to begin subsequent to initiation of the clinical trials in GBM and pancreatic cancer.